Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus FOLFOX versus bevacizumab plus FOLFIRI before resection of colorectal cancer metastases
2012-005376-34Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Dec 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, oxaliplatin, irinotecan, fluorouracil in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by Cliniques universitaires Saint-Luc. Started Dec 2012; status: completed.
02
Drugs
bevacizumaboxaliplatinirinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-005376-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005376-34.